qiagen investor relations

A total of 62% of the issued share capital of QIAGEN were represented based on 228,467,464 shares entitled to vote at the meeting (excluding 2,361,798.33 shares held in treasury by QIAGEN and 46.34 fractional shares). As of March 31, 2020, QIAGEN employed approximately 5,100 people in over 35 locations worldwide. This report, which is only for statutory purposes, can be accessed on QIAGEN’s website at: QIAGEN N.V. further announced today that it had posted its 2019 Financial Report on its website at QIAGEN's Annual Report on Form 20-F for the year ended December 31, 2019, was filed with the U.S. Securities and Exchange Commission (SEC) on March 2, 2020, a copy of which can be found on the website of the SEC at QIAGEN will provide printed copies of the 2019 Annual Report to shareholders free of charge upon request. WALTHAM, Mass., Aug. 4, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today confirmed that its offer to acquire all of QIAGEN's ordinary shares for an increased price of €43.00 per share in cash will expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020. QIAGEN N.V. hereby announces that the FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2020, was filed with the UNITED STATES SECURITIES AND EXCHANGE COMMISSION (SEC). Public Relations Thomas Theuringer +49 2103 29 11826. The tender offer materials, including the offer document and the related letter of transmittal and certain other tender offer documents, and the solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or QIAGEN, may be obtained free of charge at the SEC’s website at QIAGEN shareholders approve all agenda items related to acquisition by Thermo Fisher Scientific at Annual General Meeting Among the annually recurring agenda items adopted by shareholders were the discharge of the Managing Board and Supervisory board for the performance of their duties in 2019, as well as the re-election of all Supervisory Board members: Dr. Håkan Björklund, Stéphane Bancel, Dr. Metin Colpan, Prof. Dr. Ross Levine, Prof. Dr. Elaine Mardis, Lawrence Rosen and Elizabeth Tallett. QIAGEN’s website at www.QIAGEN.com or by contacting QIAGEN’s investor relations department at 240-686-2222 or at Thermo Fisher’swebsite at www.thermofisher.com or by contacting Thermo Fisher’s investor relations department at 781-622-1111. QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has posted its Annual Report prepared in accordance with IFRS accounting standards for the year ended December 31, 2019 on its website. Investor Presentation Download Investor Presentation Interpace Biosciences is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics.

Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com.

As previously disclosed, due to the COVID-19 pandemic, this year’s Annual General Meeting was held as a virtual event in line with Dutch legislation. Robert Reitze The Offer acceptance period commenced on May 18, 2020, and is currently scheduled to end on July 27, 2020, 24:00 hours CEST (18:00 hours New York local time).